Abstract
Molecular modeling of G-protein coupled receptors (GPCRs) remains a challenge due to the limited availability of structural information for the receptors. Molecular modeling approaches for melanocortin receptors (MCRs) fall into three categories: structurebased, ligand-based, and proteochemometric. Homology modeling combined with the information obtained from site-directed mutagenesis of receptors, recombined chimeric mutations of receptors and the structures of melanocortin type 4 receptor (MC4R) peptide ligands, has provided insights on detailed ligand-receptor interactions. Still, homology models based on the structures of bacteriorhodopsin (bR) or bovine rhodopsin as templates have not reached atomic level accuracy, making them unsuitable for rational drug design. On the other hand, availability of a large number of potent ligands of MCRs, especially those for the therapeutically important MC4R, has fueled ligand-based approaches, including automated pharmacophore query optimization and pharmacophorebased virtual screening. Proteochemometrics, a novel technology for the analysis of intermolecular interactions between ligand and receptor, has also shown great value in obtaining detailed informaton on molecular recognition and providing guidance to ligand design. In this review, the strengths and limitations of homology modeling, pharmacophore modeling and proteochemometrics modeling of MCRs are evaluated.
Keywords: double loop cross validation, Pharmacophore modeling, bovine rhodopsin, GLY-GLY combination, MSH analogues
Current Topics in Medicinal Chemistry
Title: Molecular Modeling of Melanocortin Receptors
Volume: 7 Issue: 11
Author(s): Hongmao Sun and David Fry
Affiliation:
Keywords: double loop cross validation, Pharmacophore modeling, bovine rhodopsin, GLY-GLY combination, MSH analogues
Abstract: Molecular modeling of G-protein coupled receptors (GPCRs) remains a challenge due to the limited availability of structural information for the receptors. Molecular modeling approaches for melanocortin receptors (MCRs) fall into three categories: structurebased, ligand-based, and proteochemometric. Homology modeling combined with the information obtained from site-directed mutagenesis of receptors, recombined chimeric mutations of receptors and the structures of melanocortin type 4 receptor (MC4R) peptide ligands, has provided insights on detailed ligand-receptor interactions. Still, homology models based on the structures of bacteriorhodopsin (bR) or bovine rhodopsin as templates have not reached atomic level accuracy, making them unsuitable for rational drug design. On the other hand, availability of a large number of potent ligands of MCRs, especially those for the therapeutically important MC4R, has fueled ligand-based approaches, including automated pharmacophore query optimization and pharmacophorebased virtual screening. Proteochemometrics, a novel technology for the analysis of intermolecular interactions between ligand and receptor, has also shown great value in obtaining detailed informaton on molecular recognition and providing guidance to ligand design. In this review, the strengths and limitations of homology modeling, pharmacophore modeling and proteochemometrics modeling of MCRs are evaluated.
Export Options
About this article
Cite this article as:
Hongmao Sun and David Fry , Molecular Modeling of Melanocortin Receptors, Current Topics in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/156802607780906573
DOI https://dx.doi.org/10.2174/156802607780906573 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reducing Anxiety of Pregnant Women with a History of Pregnancy Loss-A Randomize Clinical Trial
Current Women`s Health Reviews Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Drug Resistance and Methylation in Myelodysplastic Syndrome
Current Pharmaceutical Biotechnology MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Anandamide Dysfunction in Prodromal and Established Psychosis
Current Pharmaceutical Design The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease
Current Drug Targets - CNS & Neurological Disorders Effect of Trichostatin A on Gelsolin Levels, Proteolysis of Amyloid Precursor Protein, and Amyloid Beta-Protein Load in the Brain of Transgenic Mouse Model of Alzheimer's Disease
Current Alzheimer Research Crohns Targeted Therapy: Myth or Real Goal?
Current Drug Discovery Technologies Symmetry Plane Detection in Brain Image Analysis: A Survey
Current Medical Imaging Advances in the Treatment of Autoimmune Diseases; Cellular Activity, Type-1/Type-2 Cytokine Secretion Patterns and their Modulation by Therapeutic Peptides
Current Medicinal Chemistry Molecularly Imprinted Polymers: Novel Discovery for Drug Delivery
Current Drug Delivery Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Von Willebrand Factor: Drug and Drug Target
Cardiovascular & Hematological Disorders-Drug Targets Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism